Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007–13
- 28 April 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 70 (8) , 2199-2202
Abstract
The goal of this study was to characterize Streptococcus pneumoniae demonstrating MDR (resistant to three or more antimicrobial classes) or XDR (resistant to five or more classes) phenotypes, collected from Canada during the CANWARD 2007–13 study. From 2007 to 2013 inclusive, S. pneumoniae isolates were collected as a part of the CANWARD surveillance study. MDR and XDR isolates were subjected to PFGE, MLST, molecular detection of pneumococcal pili and macrolide resistance determinants mef(A/E) and erm(B), sequencing of PBPs 1A, 2B and 2X and comparison with Pneumococcal Molecular Epidemiology Network (PMEN) clones. Of 2129 S. pneumoniae isolates collected during the CANWARD 2007–13 study, 61 (2.9%) were found to be MDR. Of these MDR isolates, 43 (70.5%) were XDR. The most common serotypes for both MDR and XDR S. pneumoniae were 19A and 19F. Twenty-nine of 61 isolates (48%) demonstrated resistance to clarithromycin, clindamycin, doxycycline, penicillin and trimethoprim/sulfamethoxazole. All isolates possessed at least one macrolide resistance determinant and mutations in PBPs 1A, 2B and 2X. The most common clone was piliated, XDR ST320, an internationally circulating double-locus variant of Taiwan19F-14 (ST236). Though the rate of MDR S. pneumoniae has remained relatively stable since 2007, XDR strains have emerged in Canada. These strains are virulent, possess resistance determinants and are related to international clones.Keywords
Funding Information
- CANWARD
- University of Manitoba, Winnipeg, Health Sciences Centre
- Public Health Agency of Canada—National Microbiology Laboratory; Abbott Laboratories Ltd
- Cubist Pharmaceuticals Inc.
- Merck Canada Inc.; and Pfizer Canada Inc
This publication has 17 references indexed in Scilit:
- Predominance of ST320 among Streptococcus pneumoniae serotype 19A isolates from 10 Asian countriesJournal of Antimicrobial Chemotherapy, 2011
- Re-emergence of the type 1 pilus among Streptococcus pneumoniae isolates in Massachusetts, USAVaccine, 2010
- Increase in Pilus Islet 2–encoded Pili among Streptococcus pneumoniae Isolates, Atlanta, Georgia, USAEmerging Infectious Diseases, 2010
- Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year periodClinical Microbiology and Infection, 2010
- Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate VaccineThe Journal of Infectious Diseases, 2010
- Streptococcus pneumoniae: Epidemiology, Risk Factors, and Strategies for PreventionSeminars in Respiratory and Critical Care Medicine, 2009
- Population Snapshot of EmergentStreptococcus pneumoniaeSerotype 19A in the United States, 2005The Journal of Infectious Diseases, 2008
- Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004)Journal of Antimicrobial Chemotherapy, 2007
- Molecular characterisation of Canadian paediatric multidrug-resistant Streptococcus pneumoniae from 1998–2004International Journal of Antimicrobial Agents, 2006
- Molecular Analysis of the Genetic Variation among Penicillin‐Susceptible and Penicillin‐ResistantStreptococcus pneumoniaeSerotypes in CanadaThe Journal of Infectious Diseases, 1999